Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was conducted using clinical data of Japanese patien...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	BMC Cancer
المؤلفون الرئيسيون:	Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2022-01-01
الموضوعات:	unresectable pancreatic cancer nomogram prognosis overall survival chemotherapy
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12885-021-09139-y